Hypertrophic cardiomyopathy (Hypertrophic CardioMyopathy=HCM) remains a poorly understood disease with an assumption insufficiently codified. There is no data available in France on the profile of patients, diagnostic methods and assessment and therapeutic use. The purpose of this study is to establish a monitoring of patients with HCM (sarcomere of origin or not) in France (diagnosis, treatment)
This both retrospective and prospective study is proposed to cardiology services 50 hospitals in France. A cardiologist referral is designated for each facility. The following data will be collected by the physician during the initial hospitalization * Demographics * Geographic origin of patient * Clinical data: criteria for inclusion and non-inclusion data HCM general, Doppler ultrasound, personal history, family history * Reviews made: non-organic, biological * Family Survey, * Treatments: Medical, Electrical, invasive * Data from hospital The follow-up to 18 months, 3 years and 5 years will be conducted by clinical-research-technicians of the French Society of Cardiology, an application will be made to municipalities of birth and mail a letter to physicians and patients. The following data will be collected: * Vital status * Data from hospital * Reviews made: non-organic, biological * Treatments: Medical, Electrical, invasive
Study Type
OBSERVATIONAL
Enrollment
600
European Georges Pompidou Hospital
Paris, France
RECRUITINGEvent-free survival
Time frame: 3 years
Diagnostic methods
Define the profile of patients with HCM in France, diagnostic methods, evaluation (diagnostic investigation and family) and therapeutic. Who are the patients CMH France? (rules discovery, clinical presentation) and how are assumed the HCM in France? (examinations, hospitalizations, treatments, procedures for the family survey).
Time frame: 0 day
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.